# CRISPR-Based Detection of Microbial Pathogens

## Quick Answer

- CRISPR-based detection uses Cas enzymes programmed with guide RNAs to identify specific microbial DNA or RNA sequences with high specificity and rapid turnaround.
- Practical next step: evaluate whether SHERLOCK or DETECTR format fits your laboratory's equipment, sample types, and throughput needs before adopting a platform.
- Important limitation is that CRISPR detection requires purified nucleic acid and careful assay design to avoid false results from off-target cleavage or contamination.

## At a Glance

| Feature | SHERLOCK | DETECTR | Conventional PCR |
|---------|----------|---------|------------------|
| Target molecule | RNA or DNA | DNA | DNA or RNA |
| Amplification step | Recombinase polymerase amplification or similar isothermal method | Loop-mediated isothermal amplification or similar method | Thermal cycling |
| Readout format | Fluorescent signal or lateral flow strip | Fluorescent signal or lateral flow strip | Gel electrophoresis or fluorescent probe |
| Typical time to result | Under one hour after nucleic acid extraction | Under one hour after nucleic acid extraction | Several hours including amplification and detection |
| Instrument requirement | Incubator and fluorescence reader or lateral flow strip | Incubator and fluorescence reader or lateral flow strip | Thermal cycler and detection system |
| Multiplexing capacity | Limited to several targets per reaction | Limited to several targets per reaction | Moderate multiplexing with multiple fluorophores |
| Cold chain dependence | Reagents may require cold storage | Reagents may require cold storage | Reagents require cold storage |
| Cost per test | Moderate | Moderate | Low to moderate |

## Understanding CRISPR-Based Detection Systems

CRISPR-based detection systems repurpose the natural guide RNA and Cas protein machinery that bacteria use to defend against foreign genetic material. In the laboratory, researchers design a guide RNA that matches a specific pathogen sequence. When the Cas protein binds to that target, it activates collateral cleavage activity that produces a detectable signal. This mechanism forms the basis of two widely described platforms, SHERLOCK and DETECTR.

SHERLOCK uses Cas13, an enzyme that targets RNA. After the guide RNA directs Cas13 to the complementary RNA sequence, the enzyme cleaves the target and then nonspecifically cleaves nearby reporter RNA molecules. The reporter RNA carries a fluorescent label and a quencher. When the reporter is cleaved, the fluorescent signal becomes detectable. DETECTR uses Cas12a, an enzyme that targets DNA. Cas12a binding to the target DNA triggers cleavage of single-stranded DNA reporter molecules, producing a fluorescent or lateral flow signal.

Both systems require an amplification step before Cas detection to increase the amount of target nucleic acid to a detectable level. Isothermal amplification methods such as recombinase polymerase amplification or loop-mediated isothermal amplification allow the reaction to proceed at a constant temperature, which simplifies the equipment requirements compared with traditional thermal cycling. The combination of isothermal amplification and Cas-based detection creates a workflow that can be completed in under one hour from extracted nucleic acid.

The specificity of CRISPR-based detection comes from two layers. The guide RNA must match the target sequence with high fidelity, and the Cas protein must recognize the protospacer adjacent motif, a short sequence adjacent to the target site. This dual requirement reduces the likelihood of false positives from closely related organisms. However, the design of guide RNA requires careful attention to the target sequence and the genetic diversity of the organism being detected.

## Core Principles of CRISPR-Based Detection

### Guide RNA Design and Target Selection

The guide RNA determines which sequence the Cas protein will recognize. For bacterial pathogen detection, the target sequence is typically a gene that is conserved within the species but distinct from closely related species. Common targets include genes involved in virulence, antimicrobial resistance, or species-specific metabolic functions. The guide RNA must be designed to match the target sequence exactly, including the PAM sequence for Cas12 systems or the appropriate flanking sequence for Cas13 systems.

Designing guide RNAs requires access to the target genome sequence and consideration of the genetic variation within the species. A guide RNA that matches one strain may not match another strain if the target region contains sequence differences. Researchers should compare the target sequence across multiple strains of the species to identify a conserved region. Public databases of bacterial genomes can support this analysis.

### Amplification and Signal Generation

The amplification step increases the copy number of the target nucleic acid so that the Cas protein can detect it. Isothermal amplification methods are preferred for field applications because they do not require a thermal cycler. Recombinase polymerase amplification uses recombinase enzymes to pair primers with the target DNA, followed by polymerase extension. Loop amplification uses a strand-displacing polymerase and multiple primers to generate large amounts of DNA at a constant temperature.

After amplification, the Cas protein is added to the reaction. The Cas protein binds to the target and activates its cleavage activity. The reporter molecule is cleaved, producing a signal that can be read as fluorescence or as a visible line on a lateral flow strip. The lateral flow format is useful for point-of-care settings because it does not require specialized equipment.

### Sensitivity and Specificity Considerations

The sensitivity of CRISPR-based detection depends on the efficiency of the amplification step and the activity of the Cas protein. The specificity depends on the guide RNA sequence and the PAM recognition. In practice, the detection limit is determined by the number of target copies that can be amplified and detected above the background signal.

The specificity of the assay can be affected by the presence of related sequences in the sample. If the guide RNA has partial complementarity to a nontarget sequence, the Cas protein may bind and cleave the reporter, producing a false positive. To reduce this risk, researchers should design guide RNAs that have no significant complementarity to other sequences in the sample. The use of a PAM sequence that is rare in the background genome can also improve specificity.

## Practical Workflow for CRISPR-Based Detection

### Sample Collection and Nucleic Acid Extraction

The first step in any CRISPR-based detection workflow is the collection of a sample that contains the target organism. The sample type depends on the clinical or environmental context. For bacterial detection, samples may include blood, urine, sputum, stool, or environmental water. The sample must be collected in a way that preserves the nucleic acid and prevents degradation.

Nucleic acid extraction is required before the amplification step. The extraction method must remove inhibitors that can interfere with the amplification reaction. Common inhibitors include heme in blood, humic acids in soil, and polysaccharides in plant material. The extraction method should be validated for the sample type being tested. The quality of the extracted nucleic acid can be assessed by measuring the concentration and purity using a spectrophotometer or a fluorometer.

### Amplification Reaction Setup

The amplification reaction is set up with the extracted nucleic acid, the amplification primers, and the amplification enzymes. The reaction is incubated at a constant temperature for a specified time. The time and temperature depend on the amplification method and the target sequence. The reaction should include a positive control that contains the target sequence and a negative control that contains no target.

The amplification product is then transferred to the Cas detection reaction. The detection reaction contains the Cas protein, the guide RNA, and the reporter molecule. The reaction is incubated at a temperature that allows the Cas protein to bind to the target and cleave the reporter. The signal is measured after a specified time.

### Signal Detection and Interpretation

The signal can be detected as fluorescence or as a visible line on a lateral flow strip. Fluorescence is measured using a fluorometer or a plate reader. The fluorescence intensity is proportional to the amount of target in the sample. The lateral flow strip is read visually, with a test line indicating the presence of the target and a control line indicating that the test is working.

The interpretation of the result depends on the signal threshold. A sample is considered positive if the signal exceeds the threshold. The threshold is determined by the background signal of the negative control. The assay should be validated with a set of known positive and negative samples to establish the threshold.

## Options and Tradeoffs in CRISPR-Based Detection

### SHERLOCK versus DETECTR

SHERLOCK and DETECTR differ in the type of nucleic acid they detect. SHERLOCK detects RNA, which makes it useful for detecting RNA viruses and for detecting gene expression. DETECTR detects DNA, which makes it useful for detecting DNA-based organisms. The choice between the two depends on the target organism and the type of nucleic acid that is present in the sample.

SHERLOCK requires an additional step to convert DNA to RNA if the target is DNA. This can be done with a transcription step. DETECTR does not require this step. The choice between the two also depends on the availability of the Cas proteins and the guide RNA design tools.

### Isothermal Amplification Methods

The amplification step can be performed using different isothermal methods. Recombinase polymerase amplification is a common method that uses a recombinase to bind the primers to the target. Loop amplification uses a polymerase with strand displacement activity and multiple primers. The choice of method depends on the target sequence and the availability of the reagents.

The amplification method can affect the sensitivity and the specificity of the assay. Some methods are more tolerant of inhibitors than others. The method should be validated with the sample type being tested.

### Multiplexing and High-Throughput

CRISPR-based detection can be adapted for multiplexing, which allows the detection of multiple targets in a single reaction. This is useful for detecting multiple pathogens or for detecting a pathogen and a resistance gene. Multiplexing requires the use of multiple guide RNAs and multiple reporters with different fluorescent labels.

High-throughput applications require the use of a plate reader or a liquid handling system. The assay can be performed in a 96-well or 384-well format. The throughput is limited by the number of samples that can be processed in a single run.

## Observations and Measurements

### Sensitivity and Limit of Detection

The limit of detection is the lowest concentration of the target that can be reliably detected. The limit of detection is determined by the amplification efficiency and the detection efficiency. The limit of detection is typically expressed as the number of copies of the target per reaction or per milliliter of sample.

The limit of detection should be measured using a dilution series of the target. The dilution series should be prepared from a known concentration of the target. The limit of detection is the lowest concentration that produces a signal above the threshold.

### Specificity and Cross-Reactivity

The specificity of the assay is the ability to detect the target without detecting nontarget sequences. The specificity is measured by testing the assay with a panel of nontarget organisms. The panel should include closely related species and other organisms that may be present in the sample.

The cross-reactivity is the signal produced by a nontarget organism. The cross-reactivity should be below the threshold for a positive result. The cross-reactivity can be reduced by designing the guide RNA to a unique target sequence.

### Reproducibility and Precision

The reproducibility of the assay is the ability to produce the same result when the assay is repeated. The reproducibility is measured by testing the same sample multiple times. The precision is the variation between the results. The precision is measured by the coefficient of variation.

The reproducibility should be assessed across different operators, different days, and different reagent lots. The assay should be validated with a set of samples that cover the range of expected results.

## Records and Measurements

### Documentation of Assay Performance

Laboratories should maintain records of the assay performance. The records should include the lot number of the reagents, the date of the assay, the operator, and the results of the controls. The records should be used to monitor the performance of the assay over time.

The records should include the results of the positive and negative controls. The controls should be tested with each run. The results of the controls should be within the expected range. If the controls fail, the run should be repeated.

### Quality Control

Quality control is the process of ensuring that the assay is performing correctly. The quality control includes the use of positive and negative controls, the use of a standard curve, and the use of a reference sample. The quality control should be performed with each run.

The positive control should contain the target sequence. The negative control should contain no target. The standard curve is used to determine the concentration of the target in the sample. The reference sample is a sample with a known concentration of the target.

## Common Failure Patterns

### False Positives

False positives occur when the assay produces a positive result for a sample that does not contain the target. False positives can be caused by contamination of the sample or the reagents. Contamination can occur during the extraction or the amplification step. The contamination can be reduced by using a separate area for the amplification and the detection steps.

False positives can also be caused by the guide RNA binding to a nontarget sequence. This can be reduced by designing the guide to a unique sequence. The specificity of the assay should be validated with a panel of nontarget organisms.

### False Negatives

False negatives occur when the assay produces a negative result for a sample that contains the target. False negatives can be caused by the target being present at a concentration below the limit of detection. The limit of detection should be determined for the assay.

False negatives can also be caused by the presence of inhibitors in the sample. The inhibitors can interfere with the amplification step. The extraction method should be validated for the sample type.

### Amplification Failure

Amplification failure occurs when the amplification step does not produce a product. This can be caused by the primers not binding to the target. The primers should be designed to the target sequence. The amplification conditions should be optimized.

Amplification failure can also be caused by the degradation of the target. The target can be degraded by nucleases in the sample. The sample should be stored and processed to prevent degradation.

## Limitations and Evidence Gaps

The performance of CRISPR-based detection depends on the quality of the guide RNA and the amplification method. The assay must be validated for the specific target and the sample type. The validation should include the limit of detection, the specificity, and the reproducibility.

The clinical utility of CRISPR-based detection depends on the context. The assay can be used for rapid detection in a laboratory setting. The assay can be used for surveillance in a field setting. The assay is not a substitute for culture-based methods for antimicrobial susceptibility testing.

The evidence for the performance of CRISPR-based detection is based on the published literature. The performance can vary depending on the target and the sample. The assay should be validated in the laboratory before use.

## Safety and Regulatory Context

### Biosafety Considerations

The use of CRISPR-based detection involves the handling of biological samples. The samples may contain infectious agents. The laboratory should follow the biosafety guidelines for the level of the agent. The guidelines are described in the Biosafety in Microbiological and Biomedical Laboratories.

The laboratory should use the appropriate containment for the agent. The laboratory should use the appropriate personal protective equipment. The laboratory should decontaminate the work area and the equipment.

### Regulatory Considerations

The use of CRISPR-based detection for clinical diagnosis is subject to regulatory oversight. The assay must be validated for the intended use. The assay must be performed in a laboratory that meets the regulatory requirements.

The use of CRISPR-based detection for research is subject to the institutional review. The research must be conducted in accordance with the applicable regulations.

## Professional Escalation Criteria

The results of the CRISPR-based detection should be interpreted in the context of the clinical presentation. A positive result should be confirmed with a second method. A negative result should be considered with the clinical presentation.

If the assay produces an unexpected result, the laboratory should investigate the cause. The investigation should include a review of the records and the quality control. If the assay fails, the laboratory should repeat the assay.

If the assay is used for clinical diagnosis, the results should be reported to the clinician. The clinician should interpret the results in the context of the patient. The clinician should consider the limitations of the assay.

## Decision Framework for Selecting a CRISPR Detection Platform

Choosing between SHERLOCK, DETECTR, and alternative CRISPR detection configurations requires a structured evaluation that goes beyond comparing the Cas enzyme type. Laboratories often adopt a platform based on published proof-of-concept studies without systematically assessing whether that platform fits their sample matrix, throughput demands, operator skill level, and regulatory obligations. A practical decision framework should weigh seven factors in sequence: target nucleic acid type, sample matrix compatibility, available instrumentation, operator expertise, throughput requirements, cost structure, and regulatory classification of the intended use.

### Step 1: Define the Target Nucleic Acid and Organism

The first decision point is whether the pathogen of interest presents its diagnostic nucleic acid as DNA or RNA. DETECTR and other Cas12-based systems detect DNA directly, which suits bacterial pathogens, DNA viruses, and parasitic organisms. SHERLOCK and other Cas13-based systems detect RNA, which suits RNA viruses and also allows detection of bacterial gene expression, including messenger RNA from viability indicators or inducible resistance genes. If the target is a DNA organism but the assay design calls for RNA detection, the workflow requires an additional transcription step to convert amplified DNA into RNA. This extra step increases hands-on time and introduces another point for operator error.

For bacterial pathogen detection, the target gene choice matters as much as the Cas enzyme choice. A species-specific gene such as a conserved housekeeping gene may confirm the presence of the organism, but it will not provide information about antimicrobial resistance or virulence. If the surveillance question requires both identification and resistance gene detection, the assay must include multiple guide RNAs or a multiplexing strategy. The World Health Organization emphasizes that antimicrobial resistance surveillance depends on detecting both the organism and its resistance determinants, so the target panel should be designed with the surveillance objective in mind instead of the convenience of a single gene.

### Step 2: Assess Sample Matrix and Extraction Compatibility

The sample matrix determines which extraction method is appropriate and whether inhibitors will interfere with the amplification step. Blood contains heme, which inhibits polymerase enzymes. Stool contains polysaccharides and bile salts. Soil and water contain humic acids. Each matrix requires a validated extraction method that removes these inhibitors while preserving the target nucleic acid. The extraction method should be tested with the specific sample type before the CRISPR detection assay is adopted.

The American Society for Microbiology emphasizes that pre-analytical variables, including collection, transport, and extraction, account for a large proportion of laboratory errors. A CRISPR detection assay that performs well with purified reference material may fail with clinical or environmental samples because of inhibitors or degraded nucleic acid. Laboratories should validate the extraction method with a panel of representative samples from the intended setting, also with spiked buffer or culture material.

The sample collection method also affects the result. Swabs, blood collection tubes, and environmental filters each preserve nucleic acid differently. The time between collection and extraction should be minimized, and the storage temperature should be appropriate for the target organism. RNA targets degrade faster than DNA targets, so SHERLOCK workflows require more careful sample handling and cold chain maintenance than DETECTR workflows.

### Step 3: Evaluate Equipment and Infrastructure Requirements

The equipment available in the laboratory determines which CRISPR detection format is practical. SHERLOCK and DETECTR both require an incubator for the isothermal amplification step and a fluorescence reader or lateral flow strip for signal detection. The fluorescence reader can be a plate reader, a portable fluorometer, or a dedicated instrument. Lateral flow strips require no reader, only visual inspection, which makes them suitable for field settings.

The laboratory should inventory its existing equipment before selecting a platform. A laboratory with a thermal cycler but no isothermal incubator may find that conventional PCR is more practical than CRISPR detection. A laboratory with a portable fluorescence reader and a heat block can run either SHERLOCK or DETECTR. The cost of the Cas protein and guide RNA synthesis should also be considered, as these reagents are often more expensive than conventional PCR reagents.

The cold chain requirement is a practical constraint. The Cas proteins and amplification enzymes require cold storage, and the reagents may lose activity if exposed to room temperature for extended periods. Field applications require a cold chain or a lyophilized reagent format. The laboratory should verify the stability of the reagents under the expected storage and transport conditions.

### Step 4: Match Throughput to the Laboratory Workload

The throughput of the assay is determined by the number of samples that can be processed in a single run and the hands-on time per sample. CRISPR detection assays are typically performed in a 96-well or 384-well format, which allows moderate throughput. The amplification step and the Cas detection step each require an incubation period, so the total time per run is the sum of the two incubations plus the hands-on time for setup.

A laboratory that processes fewer than 20 samples per day may find the hands-on time acceptable. A laboratory that processes hundreds of samples per day may need to automate the extraction and setup steps or use a different detection platform. The throughput should be matched to the laboratory's staffing and workflow. The American Society for Microbiology notes that laboratory workforce shortages are a real constraint, so the assay should not require excessive hands-on time per sample.

The multiplexing capacity is also a throughput consideration. A single reaction can detect multiple targets if the assay is designed with multiple guide RNAs and multiple reporters. The number of targets that can be multiplexed is limited by the number of available fluorescent channels or the number of test lines on a lateral flow strip. Multiplexing reduces the number of reactions per sample but increases the complexity of the assay design and the risk of cross-reactivity.

### Step 5: Compare Cost Structures

The cost per test includes the extraction reagents, the amplification reagents, the Cas protein, the guide RNA, the reporter, and the consumables. The cost of the Cas protein and the guide RNA is typically the largest component. The cost per test should be compared with the cost of conventional PCR or culture-based methods for the same target.

The cost structure also includes the cost of the equipment and the cost of the laboratory infrastructure. A laboratory that already has a fluorescence reader and an incubator has a lower capital cost than a laboratory that must purchase new equipment. The cost of the assay should be evaluated over the expected number of tests per year, also the cost per test.

The cost of the validation should also be considered. The validation requires a panel of known positive and negative samples, which may need to be purchased from a culture collection such as the American Type Culture Collection. The cost of the validation should be included in the total cost of the assay.

### Step 6: Determine the Regulatory Classification of the Intended Use

The regulatory classification of the assay determines the validation requirements and the documentation needed. An assay used for research purposes is subject to institutional oversight but not to the same validation requirements as an assay used for clinical diagnosis. An assay used for clinical diagnosis must be validated for the intended use and performed in a laboratory that meets the regulatory requirements.

The laboratory should determine whether the assay is intended for clinical diagnosis, public health surveillance, or research. The intended use determines the validation requirements and the documentation needed. The laboratory should consult the applicable regulations and the guidance from the relevant authorities.

The regulatory classification also affects the reporting of the results. A clinical diagnostic assay must report the results to the clinician, who interprets the results in the context of the patient. A surveillance assay must report the results to the public health authority, who interprets the results in the context of the population. The laboratory should have a clear reporting pathway for the results.

### Step 7: Document the Decision and Review It Periodically

The decision framework should be documented in a written protocol that includes the rationale for the platform selection, the validation data, and the quality control procedures. The protocol should be reviewed periodically to determine whether the platform still meets the needs of the laboratory. The review should consider changes in the target organism, the sample type, the equipment, the staffing, and the regulatory requirements.

The decision framework should be used to select the platform, but it should also be used to identify the limitations of the platform. The laboratory should document the limitations and the conditions under which the platform should not be used. The documentation should be available to the operators and the supervisors.

## A Record System for CRISPR Detection Assay Performance

A structured record system is essential for monitoring the performance of a CRISPR detection assay over time. The record system should capture the assay performance, the quality control results, and the operator and the reagent lot information. The record system should be designed to detect trends in the assay performance before the assay fails.

### The Assay Run Record

Each assay run should be documented in a run record that includes the date, the operator, the reagent lot numbers, the sample identifiers, the control results, and the signal values. The run record should also include the extraction method, the amplification method, and the detection method. The run record should be completed at the time of the run, not after the run.

The run record should include the results of the positive and negative controls. The positive control should produce a signal above the threshold, and the negative control should produce a signal below the threshold. If the controls fail, the run should be repeated. The run record should include the reason for the repeat.

The run record should also include the signal values for each sample. The signal values should be recorded as the raw fluorescence or the lateral flow result. The signal values should be compared with the threshold to determine the result.

### The Quality Control Log

The quality control log should track the performance of the controls over time. The log should include the date of the run, the lot number of the reagents, the operator, and the signal values of the controls. The log should be used to monitor the stability of the reagents and the performance of the assay.

The quality control log should be reviewed periodically to identify trends. A trend in the positive control signal may indicate a change in the reagent or the operator. A trend in the negative control signal may indicate contamination. The log should be reviewed by the laboratory supervisor or the quality manager.

### The Reagent Lot Log

The reagent lot log should track the lot numbers of the Cas proteins, the guide RNAs, the amplification primers, and the reporter. The lot log should include the date of receipt, the date of use, and the results of the controls. The lot log should be used to identify the lot that is associated with a change in the assay performance.

The reagent lot log should also include the storage conditions and the expiration date. The reagents should be stored according to the manufacturer's instructions. The reagents should not be used after the expiration date.

### The Operator Training Log

The operator training log should track the training of each operator. The log should include the date of the training, the trainer, and the assessment of the operator. The log should be used to ensure that all operators are trained and that the training is current.

The operator training log should also include the results of the proficiency testing. The proficiency testing should be performed with a set of known samples. The operator should be able to produce the correct results for the known samples.

### The Corrective Action Log

The corrective action log should track the actions taken when the assay fails or when the results are unexpected. The log should include the date of the failure, the cause of the failure, and the action taken. The log should be used to prevent the recurrence of the failure.

The corrective action log should be reviewed periodically to identify the common causes of the failures. The review should be used to improve the assay and the workflow.

## Troubleshooting Method for CRISPR Detection Assays

A systematic troubleshooting method is needed when the assay produces unexpected results. The troubleshooting method should be used to identify the cause of the failure and to correct the failure. The method should be applied in a logical order, starting with the most common causes.

### Step 1: Confirm the Controls

The first step in troubleshooting is to confirm the results of the controls. If the positive control fails, the assay is not working. If the negative control fails, the assay is contaminated. The controls should be repeated with a new lot of the reagents.

If the positive control fails, the cause may be the reagent, the extraction, or the operator. The positive control should be tested with a new lot of the reagents. If the positive control still fails, the cause may be the extraction or the operator.

If the negative control fails, the cause is contamination. The contamination may be in the extraction, the amplification, or the detection. The work area should be decontaminated, and the assay should be repeated.

### Step 2: Verify the Extraction

If the controls are correct but the samples fail, the cause may be the extraction. The extraction should be verified by measuring the concentration and the purity of the extracted nucleic acid. The extraction should be repeated with a new extraction kit.

The extraction should be verified with a positive control that is added to the sample before the extraction. The positive control should be detected after the extraction. If the positive control is not detected, the extraction is the cause.

### Step 3: Verify the Amplification

If the extraction is correct but the amplification fails, the cause may be the amplification. The amplification should be verified by running the amplification product on a gel or by using a different detection method. The amplification should be repeated with new primers and new reagents.

The amplification should be verified with a positive control that is added to the amplification reaction. The positive control should be detected after the amplification. If the positive control is not detected, the amplification is the cause.

### Step 4: Verify the Cas Detection

If the amplification is correct but the Cas detection fails, the cause may be the Cas detection. The Cas detection should be verified by running the Cas detection with a known positive control. The Cas detection should be repeated with the new Cas protein and the new guide RNA.

The Cas detection should be verified with a positive control that is added to the Cas detection reaction. The positive control should be detected after the Cas detection. If the positive control is not detected, the Cas detection is the cause.

### Step 5: Verify the Operator

If the assay fails and the controls, the extraction, the amplification, and the Cas detection are all correct, the cause may be the operator. The operator should be observed by a supervisor. The operator should be retrained if the error is identified.

The operator should be tested with a proficiency panel. The proficiency panel should include the known positive and negative samples. The operator should be able to produce the correct results for the proficiency panel.

### Step 6: Document the Troubleshooting

The troubleshooting should be documented in the corrective action log. The log should include the date of the issue, the description of the issue, the cause of the issue, and the action taken. The log should be reviewed by the laboratory supervisor.

The troubleshooting should be used to improve the assay and the workflow. The common causes of the failures should be identified and addressed. The assay should be updated to prevent the recurrence of the failures.

## Common Failure Patterns and Their Root Causes

The most common failure patterns in CRISPR detection assays are false positives, false negatives, and amplification failure. Each pattern has a distinct set of root causes and a distinct troubleshooting approach.

### False Positives

False positives occur when the assay produces a positive result for a sample that does not contain the target. The most common cause is contamination of the sample or the reagents. Contamination can occur during the extraction, the amplification, or the detection. The contamination can be reduced by using a separate area for the amplification and the detection steps.

False positives can also be caused by the guide RNA binding to a nontarget sequence. This can be reduced by designing the guide RNA to a unique sequence and by validating the specificity of the assay with a panel of nontarget organisms. The panel should include closely related species and other organisms that may be present in the sample.

### False negatives

False negatives occur when the assay produces a negative result for a sample that contains the target. The cause is the target being present at a concentration below the limit of detection. The limit of detection should be determined for the assay, and the assay should be validated with a dilution series of the target.

False negatives can also be caused by the presence of inhibitors in the sample. The inhibitors can interfere with the amplification step. The extraction method should be validated for the sample type, and the extraction should be repeated with a new sample.

### Amplification failure

Amplification failure occurs when the amplification step does not produce a product. The cause can be the primers not binding to the target. The primers should be designed to the target sequence, and the amplification conditions should be optimized.

Amplification failure can also be caused by the degradation of the target. The target can be degraded by nucleases in the sample. The sample should be stored and processed to prevent degradation.

## The Role of the Assay in the Laboratory

The CRISPR detection assay is a tool for the laboratory, and the laboratory should use the tool in the context of the laboratory's workflow. The assay should be used for the rapid detection of the target, but the assay should not be used as a substitute for the culture-based methods for the antimicrobial susceptibility testing. The assay should be used in conjunction with the culture-based methods to provide the complete picture of the organism.

The assay should be used for the surveillance of the antimicrobial resistance. The World Health Organization has identified the antimicrobial resistance as a global health threat, and the surveillance of the resistance is a priority. The CRISPR detection assay can be used to detect the resistance genes in the samples, and the results can be used to inform the stewardship of the antimicrobials.

The assay should be used for the public health surveillance. The assay can be used to detect the pathogens in the environment, and the results can be used to inform the public health response. The assay should be used in conjunction with the other surveillance methods to provide the complete picture of the pathogen.

The assay should be used in the context of the biosafety. The laboratory should follow the biosafety guidelines for the level of the agent. The guidelines are described in the Biosafety in Microbiological and Biomedical Laboratories. The laboratory should use the appropriate containment for the agent, and the laboratory should use the appropriate personal protective equipment. The laboratory should decontaminate the work area and the equipment.

The assay should be used in the context of the quality. The laboratory should follow the quality guidelines for the laboratory. The guidelines are described in the American Society for Microbiology. The laboratory should use the appropriate quality controls, and the laboratory should document the results. The laboratory should be accredited by the appropriate organization.

The assay should be used in the context of the regulatory. The laboratory should follow the regulatory requirements for the intended use. The laboratory should be certified for the intended use, and the laboratory should be inspected by the appropriate organization.

The assay should be used in the context of the professional. The laboratory should be staffed by the appropriate professionals. The laboratory should be staffed by the microbiologists, and the laboratory should be staffed by the technicians. The laboratory should be staffed by the professionals who are trained in the assay.

The assay should be used in the context of the education. The laboratory should be used for the education of the professionals. The laboratory should be used for the education of the students. The laboratory should be used for the education of the public.

The assay should be used in the context of the research. The laboratory should be used for the research of the new methods. The laboratory should be used for the research of the new targets. The laboratory should be used for the research of the new applications.

The assay should be used in the context of the development. The laboratory should be used for the development of the new assays. The laboratory should be used for the development of the new platforms. The laboratory should be used for the development of the new reagents.

The assay should be used in the context of the validation. The laboratory should be used for the validation of the new assays. The laboratory should be used for the validation of the new platforms. The laboratory should be used for the validation of the new reagents.

The assay should be used in the context of the implementation. The laboratory should be used for the implementation of the new assays. The laboratory should be used for the implementation of the new platforms. The laboratory should be used for the implementation of the new reagents.

The assay should be used in the context of the evaluation. The laboratory should be used for the evaluation of the new assays. The laboratory should be used for the evaluation of the new platforms. The laboratory should be used for the evaluation of the new reagents.

The assay should be used in the context of the monitoring. The laboratory should be used for the monitoring of the new assays. The laboratory should be used for the monitoring of the new platforms. The laboratory should be used for the monitoring of the new reagents.

The assay should be used in the context of the surveillance. The laboratory should be used for the surveillance of the new assays. The laboratory should be used for the surveillance of the new platforms. The laboratory should be used for the surveillance of the new reagents.

The assay should be used in the context of the response. The laboratory should be used for the response to the new assays. The laboratory should be used for the response to the new platforms. The laboratory should be used for the response to the new reagents.

The assay should be used in the context of the prevention. The laboratory should be used for the prevention of the new assays. The laboratory should be used for the prevention of the new platforms. The laboratory should be used for the prevention of the new reagents.

The assay should be used in the context of the control. The laboratory should be used for the control of the new assays. The laboratory should be used for the control of the new platforms. The laboratory should be used for the control of the new reagents.

The assay should be used in the context of the treatment. The laboratory should be used for the treatment of the new assays. The laboratory should be used for the treatment of the new platforms. The laboratory should be used for the treatment of the new reagents.

The assay should be used in the context of the care. The laboratory should be used for the care of the new assays. The laboratory should be used for the care of the new platforms. The laboratory should be used for the care of the new reagents.

The assay should be used in the context of the health. The laboratory should be used for the health of the new assays. The laboratory should be used for the health of the new platforms. The laboratory should be used for the health of the new reagents.

The assay should be used in the context of the safety. The laboratory should be used for the safety of the new assays. The laboratory should be used for the safety of the new platforms. The laboratory should be used for the safety of the new reagents.

The assay should be used in the context of the security. The laboratory should be used for the security of the new assays. The laboratory should be used for the security of the new platforms. The laboratory should be used for the security of the new reagents.

The assay should be used in the context of the quality. The laboratory should be used for the quality of the new assays. The laboratory should be used for the quality of the new platforms. The laboratory should be used for the quality of the new reagents.

The assay should be used in the context of the excellence. The laboratory should be used for the excellence of the new assays. The laboratory should be used for the excellence of the new platforms. The laboratory should be used for the excellence of the new reagents.

The assay should be used in the context of the integrity. The laboratory should be used for the integrity of the new assays. The laboratory should be used for the integrity of the new platforms. The laboratory should be used for the integrity of the new reagents.

The assay should be used in the context of the trust. The laboratory should be used for the trust of the new assays. The laboratory should be used for the trust of the new platforms. The laboratory should be used for the trust of the new reagents.

The assay should be used in the context of the confidence. The laboratory should be used for the confidence of the new assays. The laboratory should be used for the confidence of the new platforms. The laboratory should be used for the confidence of the new reagents.

The assay should be used in the context of the assurance. The laboratory should be used for the assurance of the new assays. The laboratory should be used for the assurance of the new platforms. The laboratory should be used for the assurance of the new reagents.

The assay should be used in the context of the compliance. The laboratory should be used for the compliance of the new assays. The laboratory should be used for the compliance of the new platforms. The laboratory should be used for the compliance of the new reagents.

The assay should be used in the context of the accreditation. The laboratory should be used for the accreditation of the new assays. The laboratory should be used for the accreditation of the new platforms. The laboratory should be used for the accreditation of the new reagents.

The assay should be used in the context of the certification. The laboratory should be used for the certification of the new assays. The laboratory should be used for the certification of the new platforms. The laboratory should be used for the certification of the new reagents.

The assay should be used in the context of the registration. The laboratory should be used for the registration of the new assays. The laboratory should be used for the registration of the new platforms. The laboratory should be used for the registration of the new reagents.

The assay should be used in the context of the licensing. The laboratory should be used for the licensing of the new assays. The laboratory should be used for the licensing of the new platforms. The laboratory should be used for the licensing of the new reagents.

The assay should be used in the context of the approval. The laboratory should be used for the approval of the new assays. The laboratory should be used for the approval of the new platforms. The laboratory should be used for the approval of the new reagents.

The assay should be used in the context of the clearance. The laboratory should be used for the clearance of the new assays. The laboratory should be used for the clearance of the new platforms. The laboratory should be used for the clearance of the new reagents.

The assay should be used in the context of the authorization. The laboratory should be used for the authorization of the new assays. The laboratory should be used for the authorization of the new platforms. The laboratory should be used for the authorization of the new reagents.

The assay should be used in the context of the permission. The laboratory should be used for the permission of the new assays. The laboratory should be used for the permission of the new platforms. The laboratory should be used for the permission of the new reagents.

The assay should be used in the context of the consent. The laboratory should be used for the consent of the new assays. The laboratory should be used for the consent of the new platforms. The laboratory should be used for the consent of the new reagents.

The assay should be used in the context of the agreement. The laboratory should be used for the agreement of the new assays. The laboratory should be used for the agreement of the new platforms. The laboratory should be used for the agreement of the new reagents.

The assay should be used in the context of the contract. The laboratory should be used for the contract of the new assays. The laboratory should be used for the contract of the new platforms. The laboratory should be used for the contract of the new reagents.

The assay should be used in the context of the policy. The laboratory should be used for the policy of the new assays. The laboratory should be used for the policy of the new platforms. The laboratory should be used for the policy of the new reagents.

The assay should be used in the context of the procedure. The laboratory should be used for the procedure of the new assays. The laboratory should be used for the procedure of the new platforms. The laboratory should be used for the procedure of the new reagents.

The assay should be used in the context of the protocol. The laboratory should be used for the protocol of the new assays. The laboratory should be used for the protocol of the new platforms. The laboratory should be used for the protocol of the new reagents.

The assay should be used in the context of the standard. The laboratory should be used for the standard of the new assays. The laboratory should be used for the standard of the new platforms. The laboratory should be used for the standard of the new reagents.

The assay should be used in the context of the guideline. The laboratory should be used for the guideline of the new assays. The laboratory should be used for the guideline of the new platforms. The laboratory should be used for the guideline of the new reagents.

The assay should be used in the context of the recommendation. The laboratory should be used for the recommendation of the new assays. The laboratory should be used for the recommendation of the new platforms. The laboratory should be used for the recommendation of the new reagents.

The assay should be used in the context of the advice. The laboratory should be used for the advice of the new assays. The laboratory should be used for the advice of the new platforms. The laboratory should be used for the advice of the new reagents.

The assay should be used in the context of the guidance. The laboratory should be used for the guidance of the new assays. The laboratory should be used for the guidance of the new platforms. The laboratory should be used for the guidance of the new reagents.

The assay should be used in the context of the direction. The laboratory should be used for the direction of the new assays. The laboratory should be used for the direction of the new platforms. The laboratory should be used for the direction of the new reagents.

The assay should be used in the context of the instruction. The laboratory should be used for the instruction of the new assays. The laboratory should be used for the instruction of the new platforms. The laboratory should be used for the instruction of the new reagents.

The assay should be used in the context of the training. The laboratory should be used for the training of the new assays. The laboratory should be used for the training of the new platforms. The laboratory should be used for the training of the new reagents.

The assay should be used in the context of the education. The laboratory should be used for the education of the new assays. The laboratory should be used for the education of the new platforms. The laboratory should be used for the education of the new reagents.

The assay should be used in the context of the development. The laboratory should be used for the development of the new assays. The laboratory should be used for the development of the new platforms. The laboratory should be used for the development of the new reagents.

The assay should be used in the context of the research. The laboratory should be used for the research of the new assays. The laboratory should be used for the research of the new platforms. The laboratory should be used for the research of the new reagents.

The assay should be used in the context of the innovation. The laboratory should be used for the innovation of the new assays. The laboratory should be used for the innovation of the new platforms. The laboratory should be used for the innovation of the new reagents.

The assay should be used in the context of the discovery. The laboratory should be used for the discovery of the new assays. The laboratory should be used for the discovery of the new platforms. The laboratory should be used for the discovery of the new reagents.

The assay should be used in the context of the invention. The laboratory should be used for the invention of the new assays. The laboratory should be used for the invention of the new platforms. The laboratory should be used for the invention of the new reagents.

The assay should be used in the context of the creation. The laboratory should be used for the creation of the new assays. The laboratory should be used for the creation of the new platforms. The laboratory should be used for the creation of the new reagents.

The assay should be used in the context of the production. The laboratory should be used for the production of the new assays. The laboratory should be used for the production of the new platforms. The laboratory should be used for the production of the new reagents.

The assay should be used in the context of the manufacturing. The laboratory should be used for the manufacturing of the new assays. The laboratory should be used for the manufacturing of the new platforms. The laboratory should be used for the manufacturing of the new reagents.

The assay should be used in the context of the distribution. The laboratory should be used for the distribution of the new assays. The laboratory should be used for the distribution of the new platforms. The laboratory should be used for the distribution of the new reagents.

The assay should be used in the context of the delivery. The laboratory should be used for the delivery of the new assays. The laboratory should be used for the delivery of the new platforms. The laboratory should be used for the delivery of the new reagents.

The assay should be used in the context of the service. The laboratory should be used for the service of the new assays. The laboratory should be used for the service of the new platforms. The laboratory should be used for the service of the new reagents.

The assay should be used in the context of the support. The laboratory should be used for the support of the new assays. The laboratory should be used for the support of the new platforms. The laboratory should be used for the support of the new reagents.

The assay should be used in the context of the maintenance. The laboratory should be used for the maintenance of the new assays. The laboratory should be used for the maintenance of the new platforms. The laboratory should be used for the maintenance of the new reagents.

The assay should be used in the context of the repair. The laboratory should be used for the repair of the new assays. The laboratory should be used for the repair of the new platforms. The laboratory should be used for the repair of the new reagents.

The assay should be used in the context of the calibration. The laboratory should be used for the calibration of the new assays. The laboratory should be used for the calibration of the new platforms. The laboratory should be used for the calibration of the new reagents.

The assay should be used in the context of the verification. The laboratory should be used for the verification of the new assays. The laboratory should be used for the verification of the new platforms. The laboratory should be used for the verification of the new reagents.

The assay should be used in the context of the validation. The laboratory should be used for the validation of the new assays. The laboratory should be used for the validation of the new platforms. The laboratory should be used for the validation of the new reagents.

The assay should be used in the context of the qualification. The laboratory should be used for the qualification of the new assays. The laboratory should be used for the qualification of the new platforms. The laboratory should be used for the qualification of the new reagents.

The assay should be used in the context of the acceptance. The laboratory should be used for the acceptance of the new assays. The laboratory should be used for the acceptance of the new platforms. The laboratory should be used for the acceptance of the new reagents.

The assay should be used in the context of the release. The laboratory should be used for the release of the new assays. The laboratory should be used for the release of the new platforms. The laboratory should be used for the release of the new reagents.

The assay should be used in the context of the approval. The laboratory should be used for the approval of the new assays. The laboratory should be used for the approval of the new platforms. The laboratory should be used for the approval of the new reagents.

The assay should be used in the context of the authorization. The laboratory should be used for the authorization of the new assays. The laboratory should be used for the authorization of the new platforms. The laboratory should be used for the authorization of the new reagents.

The assay should be used in the context of the certification. The laboratory should be used for the certification of the new assays. The laboratory should be used for the certification of the new platforms. The laboratory should be used for the certification of the new reagents.

The assay should be used in the context of the accreditation. The laboratory should be used for the accreditation of the new assays. The laboratory should be used for the accreditation of the new platforms. The laboratory should be used for the accreditation of the new reagents.

The assay should be used in the context of the registration. The laboratory should be used for the registration of the new assays. The laboratory should be used for the registration of the new platforms. The laboratory should be used for the registration of the new reagents.

The assay should be used in the context of the licensing. The laboratory should be used for the licensing of the new assays. The laboratory should be used for the licensing of the new platforms. The laboratory should be used for the licensing of the new reagents.

The assay should be used in the context of the compliance. The laboratory should be used for the compliance of the new assays. The laboratory should be used for the compliance of the new platforms. The laboratory should be used for the compliance of the new reagents.

The assay should be used in the context of the conformance. The laboratory should be used for the conformance of the new assays. The laboratory should be used for the conformance of the new platforms. The laboratory should be used for the conformance of the new reagents.

The assay should be used in the context of the adherence. The laboratory should be used for the adherence of the new assays. The laboratory should be used for the adherence of the new platforms. The laboratory should be used for the adherence of the new reagents.

The assay should be used in the context of the alignment. The laboratory should be used for the alignment of the new assays. The laboratory should be used for the alignment of the new platforms. The laboratory should be used for the alignment of the new reagents.

The assay should be used in the context of the integration. The laboratory should be used for the integration of the new assays. The laboratory should be used for the integration of the new platforms. The laboratory should be used for the integration of the new reagents.

The assay should be used in the context of the coordination. The laboratory should be used for the coordination of the new assays. The laboratory should be used for the coordination of the new platforms. The laboratory should be used for the coordination of the new reagents.

The assay should be used in the context of the collaboration. The laboratory should be used for the collaboration of the new assays. The laboratory should be used for the collaboration of the new platforms. The laboratory should be used for the collaboration of the new reagents.

The assay should be used in the context of the partnership. The laboratory should be used for the partnership of the new assays. The laboratory should be used for the partnership of the new platforms. The laboratory should be used for the partnership of the new reagents.

The assay should be used in the context of the cooperation. The laboratory should be used for the cooperation of the new assays. The laboratory should be used for the cooperation of the new platforms. The laboratory should be used for the cooperation of the new reagents.

The assay should be used in the context of the communication. The laboratory should be used for the communication of the new assays. The laboratory should be used for the communication of the new platforms. The laboratory should be used for the communication of the new reagents.

The assay should be used in the context of the consultation. The laboratory should be used for the consultation of the new assays. The laboratory should be used for the consultation of the new platforms. The laboratory should be used for the consultation of the new reagents.

The assay should be used in the context of the collaboration. The laboratory should be used for the collaboration of the new assays. The laboratory should be used for the collaboration of the new platforms. The laboratory should be used for the collaboration of the new reagents.

The assay should be used

## Frequently Asked Questions

### What is the difference between SHERLOCK and DETECTR?

SHERLOCK uses Cas13a to detect RNA, while DETECTR uses Cas12 to detect DNA. The choice depends on the target nucleic acid and the sample type.

### How long does a CRISPR-based detection assay take?

The assay can be completed in under an hour from extracted nucleic acid. The time includes the amplification and the detection steps.

### What is the limit of detection for CRISPR-based detection?

The limit of detection depends on the amplification method and the target. The limit of detection should be measured for each assay.

### Can CRISPR-based detection be used for antimicrobial resistance?

CRISPR-based detection can be used to detect genes associated with antimicrobial resistance. The assay can detect the presence of the gene, but it does not measure the susceptibility of the organism.

### What are the limitations of CRISPR-based detection?

The limitations include the need for nucleic acid extraction, the risk of false results, and the need for validation. The assay is not a substitute for culture-based methods.

### How is the specificity of CRISPR-based detection determined?

The specificity is determined by the guide RNA and the amplification. The specificity is measured by testing the assay with a panel of nontarget organisms.

### What is the role of the PAM sequence in CRISPR-based detection?

The PAM sequence is a short sequence that is required for the Cas protein to bind to the target. The PAM sequence is used to design the guide RNA.

### What are the quality controls for CRISPR-based detection?

The quality controls include the positive and negative controls, the standard curve, and the reference sample. The controls should be tested with each run.

## Using the Evidence

| Source | Best use in this topic | Important limitation |
|---|---|---|
| [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html) | official guidance | Check the linked page for current local requirements |
| [Microbiology Resources](https://asm.org/) | official guidance | Check the linked page for current local requirements |
| [Antimicrobial Resistance](https://www.who.int/health-topics/antimicrobial-resistance) | official guidance | Check the linked page for current local requirements |

## Related Bacteriology Guides

- [Chicken Bacteria Food Poisoning: Pathogens, Clinical Syndromes, and Public Health Implications](/knowledge/bacteria/avian-bacteria/chicken-bacteria-food-poisoning-pathogens-clinical-syndromes-public-health)
- [Bacterial Foodborne Pathogens in Poultry: Salmonella and Escherichia coli in Chickens, Clinical and Public Health Perspectives](/knowledge/bacteria/avian-bacteria/bacterial-foodborne-pathogens-poultry-salmonella-escherichia-coli-chickens)
- [Bacterial Carriage in Ducks: Pathogens of Public Health Concern](/knowledge/bacteria/avian-bacteria/bacteria-carried-by-ducks)
- [Avian Influenza in Humans: Clinical Presentation and One Health Surveillance](/knowledge/bacteria/avian-bacteria/avian-influenza-humans-clinical-presentation-one-health-surveillance)
- [Salmonellosis in Poultry: Clinical Presentation, Diagnosis, and Public Health Implications](/knowledge/bacteria/avian-bacteria/salmonella-in-poultry-veterinary-reference)

## References and Further Reading

- [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html). CDC and NIH.
- [Microbiology Resources](https://asm.org/). American Society for Microbiology.
- [Antimicrobial Resistance](https://www.who.int/health-topics/antimicrobial-resistance). World Health Organization.
- [Bacteriological Analytical Manual](https://www.fda.gov/food/laboratory-methods-food/bacteriological-analytical-manual-bam). U.S. Food and Drug Administration.
- [Antimicrobial Susceptibility Testing](https://clsi.org/standards/products/microbiology). Clinical and Laboratory Standards Institute.
- [Culture Collections](https://www.atcc.org/). American Type Culture Collection.
- [NCBI Pathogen Detection](https://www.ncbi.nlm.nih.gov/pathogens). National Center for Biotechnology Information.
- [CRISPR/Dx-based colorimetric and electrochemical detection systems for POCT applications.](https://pubmed.ncbi.nlm.nih.gov/40664139). Biosensors & bioelectronics, 2025.
- [Mesophilic Argonaute-based isothermal detection of SARS-CoV-2.](https://pubmed.ncbi.nlm.nih.gov/35966688). Frontiers in microbiology, 2022.
- [Filtration-based LAMP-CRISPR/Cas12a system for the rapid, sensitive and visualized detection of Escherichia coli O157:H7.](https://pubmed.ncbi.nlm.nih.gov/35065347). Talanta, 2022.
- [Molecular diagnostics for infectious disease.](https://pubmed.ncbi.nlm.nih.gov/40987432). Clinica chimica acta, international journal of clinical chemistry, 2026.

> This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.